Navigation Links
Novelos Therapeutics Successfully Completes Second Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
Date:9/11/2012

MADISON, Wis., Sept. 11, 2012 /PRNewswire/ -- Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that it has successfully completed the second cohort in a U.S. multi-center Phase 1b dose-escalation trial of its cancer-targeted molecular radiotherapeutic compound I-131-CLR1404 (HOT) in cancer patients with advanced solid tumors.  The second two-patient cohort was successfully dosed with approximately 40 mCi of HOT, triggering enrollment into the third cohort at approximately 60 mCi.  Details of the trial design are available on www.clinicaltrials.gov ID: NCT01495663, or at www.novelos.com in the 'Clinical Trials' section.  Glenn Liu, M.D., Associate Professor of Medicine and Director of the Cancer Therapy Discovery and Development (Phase I) Program at the University of Wisconsin Carbone Cancer Center, is the trial's principal investigator.  Detailed trial results are expected to be presented at a scientific venue at a later date.

"Data from this second cohort indicates that HOT was well-tolerated, without any dose-limiting or sub-dose-limiting toxicities, enabling enrollment of the third cohort as planned," said Dr. Liu.  "We continue to observe selective uptake of HOT in cancerous tumors where it persists for at least 21 days."

"We are pleased with HOT's safety profile and selective cancerous tumor uptake and retention in this second cohort at a dose of approximately 40 mCi," said Kim Hawkins, Vice President of Clinical Development of Novelos.  "We now look forward to evaluating HOT at approximately 60 mCi in cancer patients with advanced solid tumors, as per the trial protocol."

"We expect to begin HOT Phase 2 proof-of-concept trials in the third quarter of 2013 in cancer patients that have significant unmet medical need," said Harry
'/>"/>

SOURCE Novelos Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
2. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
3. Novelos Therapeutics Prices $5.4 Million Public Offering
4. Novelos Therapeutics to Present at LHA Life Sciences & Medical Technologies Virtual Conference on June 28
5. Novelos Therapeutics to Present at Rodman & Renshaw 14th Annual Healthcare Conference on September 11
6. Novelos Therapeutics And Academic Collaborators Present Three Posters At 2012 World Molecular Imaging Congress
7. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
8. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
9. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
10. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
11. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014  ACI Clinical ( www.aciclinical.com ... Data Monitoring Committees. Using this solution, ... over industry standard costs and receive the same ... in committee services. Leveraging a decade ... contracting, charter development, statistical programming and meeting facilitation), ...
(Date:8/21/2014)... PARK, N.J. , Aug. 21, 2014 /PRNewswire/ ... pharmacy group purchasing organization (GPO), is pleased to ... to collaborate on a host of innovative specialty ... help Aurora deliver enhanced therapy management services to ... Management (OTM) system. Aurora will use ...
(Date:8/21/2014)... N.Y. , Aug. 21, 2014  The board ... ), a leading provider of clinical trial imaging solutions, ... been named chief financial officer, effective immediately.  Mr. Groff ... since August 2013.  He joined VirtualScopics in January 2006 ... in February 2013. "When the board of ...
Breaking Medicine Technology:ACI Clinical: Innovation and Savings in Data Safety Monitoring Committees 2Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 2Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 3VirtualScopics, Inc. Names James Groff Chief Financial Officer 2VirtualScopics, Inc. Names James Groff Chief Financial Officer 3VirtualScopics, Inc. Names James Groff Chief Financial Officer 4
... NOVATO, Calif., Aug. 30 BioMarin Pharmaceutical Inc. (Nasdaq: ... received orphan drug designation from the U.S. Food and ... insulin-like growth factor 2 and alpha glucosidase (IGF2-GAA) in ... new drug application (IND) for BMN-701 has been submitted, ...
... ROCKVILLE, Md., Aug. 30 Sequella, Inc., a ... for life-threatening infectious diseases, announced today the restatement ... University of Maryland, Baltimore (UMB), concerning certain technology ... technology patent (U.S. 6,663,846), jointly owned by Sequella ...
Cached Medicine Technology:BioMarin Receives Orphan Drug Designation from the FDA for BMN-701 for the Treatment of Pompe Disease 2BioMarin Receives Orphan Drug Designation from the FDA for BMN-701 for the Treatment of Pompe Disease 3Sequella and University of Maryland Restate Exclusive License for Jointly Owned Event Marker System Technology 2Sequella and University of Maryland Restate Exclusive License for Jointly Owned Event Marker System Technology 3
(Date:8/21/2014)... a woman is to focus on her body in ... than viewing her as a complete human being with ... a problem in the media, how does it affect ... of Women Quarterly , a SAGE journal, finds that ... to higher incidents of sexual pressure and coercion., Researchers ...
(Date:8/21/2014)... Researchers in the United Kingdom have demonstrated that advanced ... diagnose a number of rare diseases marked by childhood ... today in Ophthalmology , the journal of the ... doctors were able to tailor care specifically to a ... and money spent on diagnosis and enabling earlier treatment ...
(Date:8/21/2014)... Xarelto lawsuit ( http://www.xareltolawsuitcenter.com/ ) filings ... uncontrollable internal bleeding and other serious injuries continue to ... to court documents, a wrongful death lawsuit was filed ... of New York by the family of a Tennessee ... was allegedly caused by Xarelto. Among other thing, the ...
(Date:8/21/2014)... The report "Industrial Flue Gas ... System (FGD, DeNOx, Particulate Control, Mercury Control) by ... & Others) - Global Trends & Forecasts to ... gas treatment systems & services market with analysis ... terms of value. The industrial flue gas treatment ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 According to ... “Home Audio Equipment (Product Types - Home Theatre in-a-box, ... Market - Global Industry Analysis, Size, Share, Growth, Trends ... at USD 15.94 billion in 2012 and is expected ... a CAGR of 3.7% from 2013 to 2019. Europe ...
Breaking Medicine News(10 mins):Health News:Objectification in romantic relationships related to sexual pressure and coercion 2Health News:New DNA test for diagnosing diseases linked to childhood blindness 2Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 3Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 4Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 2Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 3Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 4Health News:Home Audio Equipment Market Expected to Reach USD 20.68 Billion in 2019 2Health News:Home Audio Equipment Market Expected to Reach USD 20.68 Billion in 2019 3
... carcinoma but relatively few patients are cured. Combined neoadjuvant ... survival but there is concern about treatment morbidity and ... research team from China used a prospective study, based ... postoperative CRT to surgery alone in patients with resectable ...
... idiopathic skeletal hyperostosis (DISH) is a common but ... people. All papers related to DISH demonstrate a ... advancing age. Various local structural lesions such as ... cervical osteophytes may lead to mechanical esophageal dysphagia. ...
... beyond the liver, researchers say , FRIDAY, April 9 ... virus are at much higher risk of developing kidney ... than 67,000 patients enrolled in the Henry Ford Health ... with hepatitis C developed kidney cancer. That,s double the ...
... , FRIDAY, April 9 (HealthDay News) -- Nearly half ... school-aged children are due to overuse -- and many ... the message from the just-launched Stop Sports Injuries campaign, ... and elite athletes, including professional golf legend Jack Nicklaus; ...
... ... New York Clinical Information Exchange, based in Buffalo, NY, has selected the Anakam to ... ... 9, 2010 -- Anakam announced today that HEALTHeLINK the Western New York Clinical Information ...
... Singapore ... procedures. With success rates topping 90 percent across a range of complex surgeries, the country ... ... National Eye Centre (SNEC) is the first and only specialist eye centre outside of ...
Cached Medicine News:Health News:Perioperative chemoradiotherapy in esophageal squamous cell carcinoma 2Health News:More Kids Falling Prey to Sports Overuse Injuries 2Health News:More Kids Falling Prey to Sports Overuse Injuries 3Health News:HEALTHeLINK Selects ANAKAM To Provide Cloud Based Community Wide Two Factor Authentication 2Health News:HEALTHeLINK Selects ANAKAM To Provide Cloud Based Community Wide Two Factor Authentication 3Health News:HEALTHeLINK Selects ANAKAM To Provide Cloud Based Community Wide Two Factor Authentication 4Health News:Singapore Performs Cutting-edge Eye Surgeries 2Health News:Singapore Performs Cutting-edge Eye Surgeries 3Health News:Singapore Performs Cutting-edge Eye Surgeries 4Health News:Singapore Performs Cutting-edge Eye Surgeries 5
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: